Six compounds studied in metabolic and incretin research models. This category spans the incretin receptor agonists — tirzepatide and retatrutide — alongside MOTS-c, AOD-9604, 5-Amino-1MQ and NAD+.
The regulatory picture differs sharply across these six and is worth knowing before you read any of them. Tirzepatide is an FDA-approved drug substance with published Phase 3 data. Retatrutide is investigational: a query to Drugs@FDA returns zero records for it, and its sponsor states it plans to file in Q1 2027. AOD-9604 is a fragment of human growth hormone rather than the full molecule. We cover the mechanism in our GLP-1 vs GIP explainer and the regulatory detail in is retatrutide FDA approved.Each compound page carries a specification block listing lot number, chromatographic purity, percentage of stated label claim, identity confirmation, analytical method and testing laboratory — or states plainly that the certificate is pending. We publish which it is rather than rounding up.All compounds in this category are supplied strictly for laboratory research use. They are not for human or veterinary use, not for consumption, and not approved by the FDA for any purpose.
Showing all 6 results
